Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well nintedanib works in treating patients with malignant
pleural mesothelioma that has come back. Nintedanib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.